Arbutus Biopharma Corporation announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2023 taking place June 21 - 24, 2023 in Vienna, Austria. Key Findings: AB-729 treatment in virally suppressed cHBV patients was well tolerated and led to mean HBsAg increases of >1.6 log10 after 24 weeks of treatment, comparable to other AB-729 studies. HBsAg levels.